Esperante is a private limited Netherlands-based seed investments company incorporated in January 2004.
Business Model:
Revenue: $12M
Employees: 2-10
Address: Esperante BV
City: Hoofddorp
State: other
Zip: 2132
Country: NL
Esperante is a private limited Netherlands-based seed investments company incorporated in January 2004. Esperante brings significant expertise and a human healthcare industry contacts network gained through up to three decades of cross-functional management experience. This background provides investment portfolio companies with extended management resources, particularly in Business Development, as a complement to Esperante&s;s financial contribution.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
12/2015 | Oxford Cancer Biomarkers | Venture Round | - |
8/2007 | Novacta Biosystems | Venture Round | 825.8k |
12/2005 | Cara Therapeutics | Series B | 4.7M |
1/2015 | Arquer Diagnostics | Venture Round | 0 |
8/2012 | Arquer Diagnostics | Seed Round | 0 |
12/2011 | Atox Bio | Series A | 0 |
3/2011 | Canbex Therapeutics | Venture Round | 2.8M |
5/2010 | Karus Therapeutics | Seed Round | 1.1M |
9/2019 | Versantis | Series B | 0 |
5/2010 | Karus Therapeutics | Venture Round | 1.1M |
3/2011 | Anergis | Series A | 20M |
2/2014 | Arquer Diagnostics | Seed Round | 0 |
4/2022 | Amlo Biosciences | Venture Round | 0 |
8/2011 | Haemostatix | Series C | - |
10/2017 | Arquer Diagnostics | Series B | 0 |
11/2012 | Haemostatix | Venture Round | 0 |
1/2013 | Cytox | Series A | 0 |
4/2022 | Amlo Biosciences | Venture Round | 0 |
9/2019 | Versantis | Series B | 0 |
10/2017 | Arquer Diagnostics | Series B | 0 |
12/2015 | Oxford Cancer Biomarkers | Venture Round | - |
1/2015 | Arquer Diagnostics | Venture Round | 0 |
2/2014 | Arquer Diagnostics | Seed Round | 0 |
1/2013 | Cytox | Series A | 0 |
11/2012 | Haemostatix | Venture Round | 0 |
8/2012 | Arquer Diagnostics | Seed Round | 0 |
12/2011 | Atox Bio | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|